FLINT—XlerateHealth, a national healthcare startup accelerator based in Louisville, Ky., announced the selection of six startup companies to its second annual cohort in Flint. The companies will participate in a 12-week intensive bootcamp, working with a team of coaches and mentors to support the successful commercialization of their business. The XLH program operates in the
LANSING – The Michigan Health Endowment Fund and several funding partners are coming together to provide $2.95 million to help 61 Michigan providers and safety net organizations ramp up telehealth efforts, which can help patients access critical care without putting themselves, their families, or their doctors at risk. While many providers have already planned for
FLINT - XLerateHealth, a Louisville, KY-based healthcare startup accelerator, has partnered with the University of Michigan to bring its Fast Forward Medical Innovation’s fastPACE biomedical entrepreneur program to XLH Flint. FFMI fastPACE is a four-week biomedical innovation and commercialization project-based course designed for life science innovators with an early stage project. More than 250 project
CANTON - TrialAssure – a software company focused on developing clinical trial transparency tools – has released Anonymize DS, the all-new software-as-a-service application that uses automation to anonymize sponsor’s clinical trial data. “As one of the first groups to automate the anonymization of datasets, our developers heard first-hand feedback from industry users during the limited
ROYAL OAK—OncoCell MDx Inc., a startup incubated at Harvard University to develop sophisticated cancer diagnosis from a simple blood sample, has raised $22.2 million in a Preferred Series B funding round. The financing was led by San Francisco-based Savitr Capital LLC, with participation from existing investors. OncoCell began operations in 2013, and since then has
ROYAL OAK — OncoCell MDx has hired Kirk Wojno, M.D., as its chief medical officer. OncoCell MDx is developing new, noninvasive molecular diagnostic assays. Wojno, a renowned urologic pathologist and expert in prostate biopsy interpretation, joins an expanding, experienced executive team. OncoCell MDx also recently announced the appointments of Mark McDonough as president and CEO
BOSTON - There is no doubt that 3D bioprinting is a technology of the future. Imagine being able to print a kidney or liver on demand. This is a stark contrast to the long wait for a donor organ today. Currently, the average wait time for a liver is 4 to 5 months and 2.5
PLYMOUTH — Materialise, the Belgian developer of software and services for the 3D printing industry with its North American headquarters in Plymouth, announced that it has received clearance from the U.S. Food and Drug Administration for its Mimics Enlight cardiovascular planning software suite. The first release will support clinicians planning complex transcatheter mitral valve replacement
ROCHESTER—OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital communication services for pharmaceutical companies to patients and healthcare providers, has announced a proposed underwritten public offering of shares of its common stock. The company sold 1,538,500 shares of its common stock at a price of $13 per share. The proceeds of the offering, before deducting
ROYAL OAK - Tember Shea, Portfolio Manager for Invest Detroit Ventures, interviews Mike Klein, CEO of Genomenon, to discuss the latest news coming out of the Ann Arbor-based gene therapy company. Mike Klein To listen, click on https://soundcloud.com/mike-brennan-841872555/e170-genomenon
